MedTrace Logo

Safety and Efficacy of NK510 to Treat NSCLC

NCT06097962 · Status: RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2026-05-20

No results posted yet for this study

Summary

This study assesses the safety and efficacy of NK510 combined with PD-(L)1 inhibitors for relapsed/refractory advanced NSCLC, with two administration routes: intravenous infusion and intrapleural perfusion for malignant pleural effusion. Eligible patients need confirmed measurable lesions; intravenous cohort requires EGFR/ROS1/ALK negativity and disease progression after PD-(L)1 inhibitor treatment, while intrapleural cohort accepts targeted therapy-resistant patients with ≥500ml pleural effusion, and the treatment's safety, efficacy and immune microenvironment changes will be evaluated.

Conditions

Interventions

DRUG

NK510

Intravenous infusion

DRUG

Tislelizumab，atezolizumab or sugemalimab

Administer according to the instructions

DRUG

NK510

intrapleural infusion

DRUG

systemic therapy as selected by the investigator

Administer according to the instructions

Sponsors & Collaborators

  • Jinling Hospital, China

    collaborator OTHER

  • Base Therapeutics (Shanghai) Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Tangfeng Lv, PhD · Jinling hospital, Nanjing, China

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-01
Primary Completion
2026-07-01
Completion
2026-07-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06097962 on ClinicalTrials.gov